Study S002075

Phase IIa Study to Evaluate the Efficacy and Safety of Subcutaneous SR-Exenatide (PT320) in Patients With Early Parkinson's Disease

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT04269642
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: UNKNOWN
Enrollment: 99
Start: 2020-03-19
Primary completion: 2021-09-29
Lead sponsor: Peptron, Inc.
Conditions: Early Parkinson's Disease
Interventions: DRUG:PT320 2.0mg Placebo; DRUG:PT320 2.0 mg; DRUG:PT320 2.5 mg
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Change of MDS-UPDRS part 3 score [48 week]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.